LabGenomics, COVID-19 (Diagnosis/Treatment/Vaccine Development, etc.) Theme Rises 6.92% Up

On the 22nd, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.07% compared to the previous day, showing strength, while LabGenomics, a related stock attracting attention, surged by 6.92% compared to the previous day. LabGenomics is known as a manufacturer of in vitro diagnostics and gene analysis services and products.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to the analysis by Thinkpool Robo Algorithm RASSI, LabGenomics ranked 7th out of 47 stocks in the quant financial ranking by exceeding the theme’s average scores in growth, stability, and profitability. This can be interpreted as LabGenomics having relatively high investment attractiveness compared to other stocks within the theme from a financial perspective.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of the Robo Algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.